{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:30:40Z","timestamp":1793813440650,"version":"4.6.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000921","name":"European Cooperation in Science and Technology","doi-asserted-by":"publisher","award":["CA22125"],"award-info":[{"award-number":["CA22125"]}],"id":[{"id":"10.13039\/501100000921","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jhepr.2026.102036","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:34:12Z","timestamp":1790098452000},"page":"102036","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world data from patients treated with chemotherapy for biliary tract cancer: Insights from a prognostic model"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8289-7741","authenticated-orcid":false,"given":"Julien","family":"Edeline","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Casadei-Gardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7147-5703","authenticated-orcid":false,"given":"Daniel","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0560-5538","authenticated-orcid":false,"given":"Arndt","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8650-0740","authenticated-orcid":false,"given":"Alexandre","family":"Peinoit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Goetgheluck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8979-3972","authenticated-orcid":false,"given":"H\u00e9lo\u00efse","family":"Bourien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2272-3678","authenticated-orcid":false,"given":"Mair\u00e9ad G.","family":"McNamara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Le Sourd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Lamarca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Rimini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Fornaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Leone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Brandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4857-4276","authenticated-orcid":false,"given":"Anna","family":"Saborowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Li\u00e8vre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Hubner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1404-0209","authenticated-orcid":false,"given":"Philip","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1999-0863","authenticated-orcid":false,"given":"Juan W.","family":"Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2026.102036_bib1","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1634\/theoncologist.2015-0446","article-title":"Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise","volume":"21","author":"Saha","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.jhepr.2026.102036_bib2","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.102036_bib3","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.jhep.2022.07.022","article-title":"Current epidemiology of cholangiocarcinoma in Western countries","volume":"77","author":"Vithayathil","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.102036_bib4","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1200\/JCO.21.02568","article-title":"Long-term outcomes and exploratory analyses of the randomized phase III BILCAP study","volume":"40","author":"Bridgewater","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhepr.2026.102036_bib5","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2026.102036_bib6","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1200\/JCO.21.00679","article-title":"Modified FOLFIRINOX versus CISGEM chemotherapy for patients with advanced biliary tract cancer (PRODIGE 38 AMEBICA): a randomized phase II study","volume":"40","author":"Phelip","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhepr.2026.102036_bib7","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"0","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jhepr.2026.102036_bib8","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","article-title":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study","volume":"9","author":"Oh","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.102036_bib9","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2026.102036_bib10","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1200\/JCO-24-01383","article-title":"SWOG 1815: a phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers","volume":"43","author":"Shroff","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhepr.2026.102036_bib11","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1470-2045(14)70212-8","article-title":"Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial","volume":"15","author":"Malka","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2026.102036_bib12","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S1470-2045(10)70247-3","article-title":"Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study","volume":"11","author":"Gruenberger","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2026.102036_bib13","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.18_suppl.lba4032","article-title":"Phase III study of gemcitabine\/oxaliplatin (GEMOX) with or without erlotinib in unresectable, metastatic biliary tract carcinoma","volume":"29","author":"Lim","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhepr.2026.102036_bib14","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(11)70301-1","article-title":"Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study","volume":"13","author":"Lee","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2026.102036_bib15","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.18.00050","article-title":"Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study","volume":"37","author":"Edeline","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhepr.2026.102036_bib16","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ejca.2019.10.004","article-title":"Modified gemcitabine and oxaliplatin or gemcitabine + cisplatin in unresectable gallbladder cancer: results of a phase III randomised controlled trial","volume":"123","author":"Sharma","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhepr.2026.102036_bib17","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/annonc\/mdt540","article-title":"Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials","volume":"25","author":"Valle","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhepr.2026.102036_bib18","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhepr.2026.102036_bib19","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1002\/sim.1203","article-title":"Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects","volume":"21","author":"Royston","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.jhepr.2026.102036_bib20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2288-13-33","article-title":"External validation of a Cox prognostic model: principles and methods","volume":"13","author":"Royston","year":"2013","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jhepr.2026.102036_bib21","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1177\/1536867X1001000303","article-title":"Comparing the predictive powers of survival models using Harrell\u2019s C or Somers\u2019 D","volume":"10","author":"Newson","year":"2010","journal-title":"Stata J"},{"key":"10.1016\/j.jhepr.2026.102036_bib22","volume":"2","author":"Ibrahim","year":"2001"},{"key":"10.1016\/j.jhepr.2026.102036_bib23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12874-025-02540-2","article-title":"Estimating treatment effects using parametric models as counter-factual evidence","volume":"25","author":"Jackson","year":"2025","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jhepr.2026.102036_bib24","series-title":"Bayesian data analysis","author":"Gelman","year":"1995"},{"key":"10.1016\/j.jhepr.2026.102036_bib26","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jhep.2021.12.010","article-title":"Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry","volume":"76","author":"Izquierdo-Sanchez","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.102036_bib27","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejca.2019.05.030","article-title":"Score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy","volume":"117","author":"Salati","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhepr.2026.102036_bib28","doi-asserted-by":"crossref","first-page":"352","DOI":"10.21037\/jgo.2017.03.06","article-title":"Long term responders to palliative chemotherapy for advanced biliary tract cancer","volume":"8","author":"Doherty","year":"2017","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.jhepr.2026.102036_bib29","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","article-title":"Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan","volume":"103","author":"Okusaka","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhepr.2026.102036_bib30","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jhep.2025.01.040","article-title":"A phase III randomized study of first-line NUC-1031\/cisplatin vs. gemcitabine\/cisplatin in advanced biliary tract cancer","volume":"83","author":"Knox","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.102036_bib31","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/sj.bjc.6604628","article-title":"Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study","volume":"99","author":"Andr\u00e9","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhepr.2026.102036_bib32","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s12885-017-3266-9","article-title":"Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials","volume":"17","author":"McNamara","year":"2017","journal-title":"BMC Cancer"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926003071?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926003071?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T16:40:46Z","timestamp":1793810446000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555926003071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2589555926003071"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.102036","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world data from patients treated with chemotherapy for biliary tract cancer: Insights from a prognostic model","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.102036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"102036"}}